Code of
Business Conduct
At Johnson & Johnson, we believe acting ethically and responsibly is not only the right thing to do, but also the right thing to do for our business. Our Johnson & Johnson Code of Business Conduct ensures that we hold ourselves and how we do business to a high standard, allowing us to fulfill our obligations to the many stakeholders we serve.
Effective May 16, 2024, Johnson & Johnson amended its Code of Business Conduct to provide enhanced guidance on addressing the evolving business environment, reflecting our commitment to compliance and responsible operations.
Effective May 16, 2024, Johnson & Johnson amended its Code of Business Conduct to provide enhanced guidance on addressing the evolving business environment, reflecting our commitment to compliance and responsible operations.
Our Credo Integrity Line
Our Credo Integrity Line is an integral component of our strong culture of integrity at Johnson & Johnson. It provides a channel for anyone (including employees, business partners, customers, consumers and others) to report potential violations of the Code of Business Conduct, other company policies or applicable laws and regulations in our countries of operation. Our Credo Integrity Line is available 24 hours a day, 7 days a week and in 24 languages.
Go to the Our Credo Integrity Line website for more information including directions for filing concerns digitally or by phone.
Go to the Our Credo Integrity Line website for more information including directions for filing concerns digitally or by phone.
Additional policies & resources
The values and principles spelled out in Our Credo serve as our compass; the Johnson & Johnson Code of Business Conduct is the road map that helps us stay on course with those values. The Code sets requirements for business conduct and serves as a foundation for our Company policies, procedures and guidelines, all of which provide additional guidance on expected behaviors.
Our Credo
The values that guide our decision-making are spelled out in Our Credo. Put simply, Our Credo challenges us to put the needs and well-being of the people we serve first.
Robert Wood Johnson, former chairman from 1932 to 1963 and a member of the Company’s founding family, crafted Our Credo himself in 1943, just before Johnson & Johnson became a publicly traded company. This was long before anyone ever heard the term “corporate social responsibility.” Our Credo is more than just a moral compass. We believe it’s a recipe for business success. The fact that Johnson & Johnson is one of only a handful of companies that have flourished through more than a century of change is proof of that.
Robert Wood Johnson, former chairman from 1932 to 1963 and a member of the Company’s founding family, crafted Our Credo himself in 1943, just before Johnson & Johnson became a publicly traded company. This was long before anyone ever heard the term “corporate social responsibility.” Our Credo is more than just a moral compass. We believe it’s a recipe for business success. The fact that Johnson & Johnson is one of only a handful of companies that have flourished through more than a century of change is proof of that.
Discover
J&J
Every day, our more than 150,000 employees across the world are blending heart, science and ingenuity to profoundly change the trajectory of health for humanity.
Our Societal Impact
Johnson & Johnson’s ESG strategy aims to improve access, create healthier communities, and put a healthy mind, body and environment within reach of all.
More from Johnson & Johnson
What to know about We All Belong: 2023 DEI Impact Review
The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.
Giving the gift of sight
In Kenya, around 1.5 million people—including children—contend with visual impairment or blindness. Sight For Kids, Johnson & Johnson’s global eye-care partnership, is devoted to changing these stats, one vision screening at a time.
Inside the development of a revolutionary treatment for blood cancers
In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.